A recent review in Diabetes Care evaluates the efficacy and safety of GLP-1 receptor agonists for type 2 diabetes and obesity, exploring their potential for new medical indications.
Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond
- Post author:
- Post published:June 18, 2024
- Post category:uncategorized